News
LTRN
2.295
-1.50%
-0.035
Lantern Pharma launches withZeta.ai
TipRanks · 1d ago
Lantern Pharma to debut withZeta.ai at Nasdaq investor briefing
PUBT · 1d ago
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
Barchart · 1d ago
Weekly Report: what happened at LTRN last week (0406-0410)?
Weekly Report · 2d ago
Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers
TipRanks · 5d ago
Weekly Report: what happened at LTRN last week (0330-0403)?
Weekly Report · 04/06 09:16
Lantern Pharma to host live demonstration of withZeta.ai
TipRanks · 04/02 12:15
Lantern Pharma to host investor webcast featuring live demo of withZeta.ai platform
Reuters · 04/02 12:10
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
Barchart · 04/02 07:10
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 03/31 21:05
Why Is Vanguard Total Stock Market ETF (VTI) Rising Today, 3/31/26?
TipRanks · 03/31 14:43
Lake Street Reaffirms Their Buy Rating on Lantern Pharma (LTRN)
TipRanks · 03/31 13:47
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/31 12:05
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify
Seeking Alpha · 03/30 23:53
Lantern Pharma Reports 2025 Results and Pipeline Progress
TipRanks · 03/30 23:04
Closing Bell Movers: Phreesia down over 20% after guidance cut
TipRanks · 03/30 22:35
LANTERN PHARMA: TO OFFER SHARES OF COMMON STOCK ON BEST EFFORTS BASIS; SIZE NOT DISCLOSED - SEC FILING
Reuters · 03/30 22:01
Lantern Pharma reports Q4 net income ($4.1M) vs ($5.9M) last year
TipRanks · 03/30 20:22
Lantern Pharma Q4 EPS $(0.36) Beats $(0.46) Estimate
Benzinga · 03/30 20:22
Lantern Pharma says article on CEO leaving ‘false and misleading’
TipRanks · 03/30 20:21
More
Webull provides a variety of real-time LTRN stock news. You can receive the latest news about Lantern Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.